Home/ Stocks/ ZNTL

Zentalis Pharmaceuticals, Inc. Common Stock

ZNTL XNAS

$2.47 -0.06 (-2.37%) ▼ 15-min delayed

Open

$2.53

High

$2.53

Low

$2.40

Volume

418.5K

Market Cap

$163.82M

About Zentalis Pharmaceuticals, Inc. Common Stock

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 166 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-26,691,000	$-0.37
Q2 2025	$0	$-26,874,000	$-0.37
Q1 2025	$0	$-48,279,000	$-0.67
FY 2024	$67.42M	$-165,867,000	$-2.33

Earnings & Analyst Ratings

Next Earnings: Tue, May 12, 2026

Calendar →

Related Market News

No specific coverage for ZNTL yet. Check out our latest market news or earnings calendar.

Get ZNTL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Zentalis Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.